Investor Relations

Developing Novel Therapeutics to Destroy Cancer

About BriaCell

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is a clinical-stage small-cap biotech immunotherapy company advancing novel approaches to fight cancer and improve patients’ lives. Focused initially on breast cancer immunotherapy, BriaCell is developing innovative off-the-shelf immunotherapy platforms with the potential to transform outcomes for patients with cancer.

Why Investors are Watching BriaCell

• Pivotal Phase 3 study: Features lead candidate Bria-IMT™ in metastatic breast cancer
• FDA Fast Track designation: Highlights urgent need and regulatory support
• Off-the-shelf immunotherapy model: Designed for scalability and personalization
• Upcoming news flow: Utilizing near-term catalysts in breast and prostate cancer
• Strong leadership: Management and board members are experts in drug development

Explore Our Clinical Pipeline

BriaCell’s pipeline focuses on immunotherapies designed to improve safety, efficacy, and accessibility for cancer patients:

• Bria-IMT™: Lead clinical candidate in a pivotal Phase 3 clinical study for metastatic breast cancer. 
• Phase 2 study showed the following:
• Overall Survival better than Phase 3 data for Trodelvy in similar patients
• Overall Survival of ~2X of competitors
• Progression Free Survival 2X of competitors
• Responses observed in patients with central nervous system (CNS) metastasis, antibody-drug conjugate (ADC) resistant and check point inhibitor (CPI) resistant patients
• Bria-OTS™: A novel "personalized off-the-shelf" immunotherapy designed to match patients HLA types to personalize treatments for better efficacy. 
• Awarded a U.S. patent, Bria-OTS™ is in Phase 1/2 clinical trials. Responses (100% Resolution of a Lung Metastasis seen in first patient. An enhanced version (Bria-OTS+™) expected to enter the clinic in early 2026 for breast cancer and prostate cancer.
• Broader Indications: Pipeline expansion includes Bria-PROS+™, an off-the-shelf immunotherapy candidate for prostate cancer. A "bucket trial" is also planned for additional cancer types.

This unique model positions BriaCell as a differentiated immunotherapy company with both near-term and long-term value creation opportunities.

Resources for Investors

• Investor Presentation
• Analyst Coverage
• FAQ Page
• Sign Up for Investor Email Alerts

Stay updated on BriaCell stock (BCTX stock info), clinical milestones, and upcoming events by joining our investor email list.